Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-06954522 IR and MR Formulations in Healthy Adults
NCT06393517Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-06954522 in type 2 diabetes mellitus (T2DM) and obesity (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve from time zero to extrapolated infinite time and Maximum Observed Plasma Concentration. Started Apr 2024; status: completed.
02
Drugs
PF-06954522
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06393517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393517.